Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling

Smita Majumder, Antonella Caccamo, David X. Medina, Adriana D. Benavides, Martin A. Javors, Ellen Kraig, Randy Strong, Arlan Richardson, Salvatore Oddo

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Understanding the factors that contribute to age-related cognitive decline is imperative, particularly as age is the major risk factor for several neurodegenerative disorders. Levels of several cytokines increase in the brain during aging, including IL-1β, whose levels positively correlate with cognitive deficits. Previous reports show that reducing the activity of the mammalian target of rapamycin (mTOR) extends lifespan in yeast, nematodes, Drosophila, and mice. It remains to be established, however, whether extending lifespan with rapamycin is accompanied by an improvement in cognitive function. In this study, we show that 18-month-old mice treated with rapamycin starting at 2months of age perform significantly better on a task measuring spatial learning and memory compared to age-matched mice on the control diet. In contrast, rapamycin does not improve cognition when given to 15-month-old mice with pre-existing, age-dependent learning and memory deficits. We further show that the rapamycin-mediated improvement in learning and memory is associated with a decrease in IL-1β levels and an increase in NMDA signaling. This is the first evidence to show that a small molecule known to increase lifespan also ameliorates age-dependent learning and memory deficits.

Original languageEnglish (US)
Pages (from-to)326-335
Number of pages10
JournalAging Cell
Volume11
Issue number2
DOIs
StatePublished - Apr 2012
Externally publishedYes

Fingerprint

N-Methylaspartate
Sirolimus
Interleukin-1
Memory Disorders
Learning
Cognition
Neurodegenerative Diseases
Drosophila
Yeasts
Cytokines
Diet
Brain

Keywords

  • Aging
  • Cytokines
  • IL-1β
  • Learning and memory
  • MTOR
  • NMDA

ASJC Scopus subject areas

  • Cell Biology
  • Aging

Cite this

Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. / Majumder, Smita; Caccamo, Antonella; Medina, David X.; Benavides, Adriana D.; Javors, Martin A.; Kraig, Ellen; Strong, Randy; Richardson, Arlan; Oddo, Salvatore.

In: Aging Cell, Vol. 11, No. 2, 04.2012, p. 326-335.

Research output: Contribution to journalArticle

Majumder, S, Caccamo, A, Medina, DX, Benavides, AD, Javors, MA, Kraig, E, Strong, R, Richardson, A & Oddo, S 2012, 'Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling', Aging Cell, vol. 11, no. 2, pp. 326-335. https://doi.org/10.1111/j.1474-9726.2011.00791.x
Majumder, Smita ; Caccamo, Antonella ; Medina, David X. ; Benavides, Adriana D. ; Javors, Martin A. ; Kraig, Ellen ; Strong, Randy ; Richardson, Arlan ; Oddo, Salvatore. / Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. In: Aging Cell. 2012 ; Vol. 11, No. 2. pp. 326-335.
@article{83a85185c31f4569b7adc86a2ba01e7f,
title = "Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling",
abstract = "Understanding the factors that contribute to age-related cognitive decline is imperative, particularly as age is the major risk factor for several neurodegenerative disorders. Levels of several cytokines increase in the brain during aging, including IL-1β, whose levels positively correlate with cognitive deficits. Previous reports show that reducing the activity of the mammalian target of rapamycin (mTOR) extends lifespan in yeast, nematodes, Drosophila, and mice. It remains to be established, however, whether extending lifespan with rapamycin is accompanied by an improvement in cognitive function. In this study, we show that 18-month-old mice treated with rapamycin starting at 2months of age perform significantly better on a task measuring spatial learning and memory compared to age-matched mice on the control diet. In contrast, rapamycin does not improve cognition when given to 15-month-old mice with pre-existing, age-dependent learning and memory deficits. We further show that the rapamycin-mediated improvement in learning and memory is associated with a decrease in IL-1β levels and an increase in NMDA signaling. This is the first evidence to show that a small molecule known to increase lifespan also ameliorates age-dependent learning and memory deficits.",
keywords = "Aging, Cytokines, IL-1β, Learning and memory, MTOR, NMDA",
author = "Smita Majumder and Antonella Caccamo and Medina, {David X.} and Benavides, {Adriana D.} and Javors, {Martin A.} and Ellen Kraig and Randy Strong and Arlan Richardson and Salvatore Oddo",
year = "2012",
month = "4",
doi = "10.1111/j.1474-9726.2011.00791.x",
language = "English (US)",
volume = "11",
pages = "326--335",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling

AU - Majumder, Smita

AU - Caccamo, Antonella

AU - Medina, David X.

AU - Benavides, Adriana D.

AU - Javors, Martin A.

AU - Kraig, Ellen

AU - Strong, Randy

AU - Richardson, Arlan

AU - Oddo, Salvatore

PY - 2012/4

Y1 - 2012/4

N2 - Understanding the factors that contribute to age-related cognitive decline is imperative, particularly as age is the major risk factor for several neurodegenerative disorders. Levels of several cytokines increase in the brain during aging, including IL-1β, whose levels positively correlate with cognitive deficits. Previous reports show that reducing the activity of the mammalian target of rapamycin (mTOR) extends lifespan in yeast, nematodes, Drosophila, and mice. It remains to be established, however, whether extending lifespan with rapamycin is accompanied by an improvement in cognitive function. In this study, we show that 18-month-old mice treated with rapamycin starting at 2months of age perform significantly better on a task measuring spatial learning and memory compared to age-matched mice on the control diet. In contrast, rapamycin does not improve cognition when given to 15-month-old mice with pre-existing, age-dependent learning and memory deficits. We further show that the rapamycin-mediated improvement in learning and memory is associated with a decrease in IL-1β levels and an increase in NMDA signaling. This is the first evidence to show that a small molecule known to increase lifespan also ameliorates age-dependent learning and memory deficits.

AB - Understanding the factors that contribute to age-related cognitive decline is imperative, particularly as age is the major risk factor for several neurodegenerative disorders. Levels of several cytokines increase in the brain during aging, including IL-1β, whose levels positively correlate with cognitive deficits. Previous reports show that reducing the activity of the mammalian target of rapamycin (mTOR) extends lifespan in yeast, nematodes, Drosophila, and mice. It remains to be established, however, whether extending lifespan with rapamycin is accompanied by an improvement in cognitive function. In this study, we show that 18-month-old mice treated with rapamycin starting at 2months of age perform significantly better on a task measuring spatial learning and memory compared to age-matched mice on the control diet. In contrast, rapamycin does not improve cognition when given to 15-month-old mice with pre-existing, age-dependent learning and memory deficits. We further show that the rapamycin-mediated improvement in learning and memory is associated with a decrease in IL-1β levels and an increase in NMDA signaling. This is the first evidence to show that a small molecule known to increase lifespan also ameliorates age-dependent learning and memory deficits.

KW - Aging

KW - Cytokines

KW - IL-1β

KW - Learning and memory

KW - MTOR

KW - NMDA

UR - http://www.scopus.com/inward/record.url?scp=84858342119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858342119&partnerID=8YFLogxK

U2 - 10.1111/j.1474-9726.2011.00791.x

DO - 10.1111/j.1474-9726.2011.00791.x

M3 - Article

C2 - 22212527

AN - SCOPUS:84858342119

VL - 11

SP - 326

EP - 335

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 2

ER -